Eutilex Co., Ltd.

Yeonji Oh

Byoung S Kwon

Jin Sung Park

Hanna Lee

Seung Hee Han

Sun Woo Im

Hyun Tae Son

Hyeok-Jun Park

Eunhye Yoo

The present invention provides a bispecific epitope binding protein comprising an anti-4-1BB agonist antibody and a PD-1 protein or a fragment thereof that binds to PD-L1 with high affinity. The bispecific epitope binding protein simultaneously and independently binds to 4-1BB and PD-L1, which engage 4-1BB upregulated T cells, especially effector CD8+ T cells, with tumor cells expressing PD-L1. These interactions induce strong activation of the cytotoxic activity of anti-tumor effector CD8+ T cells by both blocking PD-1/PD-L1-mediated inhibitory signaling and activating 4-1BB-mediated costimulatory signaling in mouse models. This bispecific epitope binding protein has a much stronger oncolytic effect compared to each component alone.

Bispecific epitope binding protein comprising anti-4-1BB antibody and a PD-1 protein or fragments thereof and use thereof

A bispecific epitope binding protein having a multimer of four single-chain chimeric polypeptides of two single-chain chimeric heavy chains and two single-chain chimeric light chains. The bispecific epitope binding protein has a first antigen binding domain that binds specifically to HER2 and a second antigen binding domain that binds specifically to 4-1BB.

Anti-HER2/anti-4-1BB bispecific antibodies and uses thereof

Growing community of inventors

Seoul, South Korea

Yeonji Oh